CNS Discovery Research, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850, USA.
Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. doi: 10.1016/j.bmcl.2010.07.112. Epub 2010 Aug 3.
Further structure activity relationship studies on a previously reported 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide series of potent and selective kappa opioid receptor antagonists is discussed. Modification of the pendant N-substitution to include a cyclohexylurea moiety produced analogs with greater in vitro opioid and hERG selectivity such as 12 (kappa IC50=172 nM, mu:kappa ratio=93, delta:kappa ratio=>174, hERG IC50=>33 microM). Changes to the linker conformation and identity as well as to the benzamide ring moiety were also investigated.
进一步讨论了先前报道的 8-氮杂双环[3.2.1]辛烷-3-氧基苯甲酰胺系列强效和选择性 κ 阿片受体拮抗剂的结构-活性关系。修饰侧链 N 取代基,引入环己基脲部分,得到了具有更高体外阿片类和 hERG 选择性的类似物,例如 12(κ IC50=172 nM,μ:κ 比值=93,δ:κ 比值>174,hERG IC50>33 μM)。还研究了连接子构象和取代基的改变以及苯甲酰胺环部分。